ERG Assesses Innovative Drug Program for FDA

An ERG interim report for a congressionally mandated assessment of FDA's review program for innovative drugs is drawing press attention. To develop the interim report, ERG analyzed extensive data about every drug application in the program and interviewed nearly every drug sponsor and FDA review team. We will present the report at a public meeting in May, so stay tuned for more details!